Publication | Open Access

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

OncologyPancreatic CancerMedicineCd40 Agonist MitazalimabImmune Checkpoint InhibitorPharmacotherapyMulticentre Phase 1B/2Cancer TreatmentPharmacologyRadiation Oncology